Conditional knockout of <scp>AIM2</scp> in microglia ameliorates synaptic plasticity and spatial memory deficits in a mouse model of Alzheimer's disease

Lei Ye, Mengsha Hu, Rui Mao, Tan Yi, Min Sun, Junqiu Jia, Siyi Xu, Yi Liu, Xiaolei Zhu, Yun Xu, Feng Bai, Shu ShuCNS Neuroscience & Therapeutics 2023 · DOI

TL;DR

Researchers have identified a key role for the inflammasome sensor AIM2, specifically within microglia, in exacerbating synaptic dysfunction and memory loss in Alzheimer's disease (AD) models. By selectively knocking out AIM2 in microglia, they were able to rescue cognitive deficits and synaptic impairments, suggesting AIM2 as a potential therapeutic target for AD.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. A central hallmark of AD is synaptic dysfunction and the loss of synapses, which are crucial for learning and memory. While the accumulation of amyloid-beta (Aβ) plaques is a known contributor, the precise mechanisms driving synapse loss are still being unraveled. Microglia, the brain's resident immune cells, are increasingly implicated, with evidence suggesting their phagocytic activity can become dysregulated in AD, leading to excessive synapse removal. Previous work hinted at the involvement of the inflammasome sensor AIM2 in AD, showing its increased expression in AD mouse models and that its complete absence improved cognitive function. However, the specific cell type and mechanism through which AIM2 exerts its detrimental effects on synapses in AD remained unclear. This study aims to pinpoint AIM2's role in microglia and elucidate how it contributes to AD-related synaptic and cognitive deficits.

Methods

The researchers employed a multi-pronged approach to investigate AIM2's role in AD:

  • AD Mouse Model: They induced an AD-like state in C57BL/6 mice by injecting Aβ1-42 into the hippocampus, a common method to mimic key aspects of AD pathology.
  • Genetic Manipulation:
    • AIM2 Overexpression: They used lentiviruses to overexpress AIM2 in the hippocampus of healthy mice to assess its direct impact on synaptic function and cognition.
  • Microglial-Specific AIM2 Knockout (AIM2-cKO): They generated mice with AIM2 specifically deleted from microglia by crossing AIM2-floxed mice with Cx3cr1-Cre mice. This allowed them to isolate the effect of AIM2 within microglia.
  • Behavioral Assessments: A battery of tests was used to evaluate cognitive function:
  • Open-field test: Assessed general locomotor activity and anxiety.
  • Novel Object Recognition (NOR) test: Measured recognition memory.
  • Morris Water Maze (MWM) test: Evaluated spatial learning and memory.
  • Molecular and Cellular Analysis:
    • Western Blotting & qRT-PCR: Quantified protein and mRNA levels of synaptic markers (PSD-95, MAP-2) and AIM2.
  • Immunofluorescence Staining: Visualized the localization of AIM2 and microglia (IBA1) and assessed synaptic markers (PSD-95) and complement proteins (C1q, C3).
  • Golgi Staining: Examined neuronal morphology, including dendritic complexity and spine density.
  • Electrophysiology: Measured synaptic function by recording field excitatory postsynaptic potentials (fEPSPs) and long-term potentiation (LTP) in hippocampal slices.
  • Complement Pathway Analysis: Investigated the expression and colocalization of complement components (C1q, C3) with microglia and synapses.

Datasets

Not discussed in the paper. The study primarily utilizes established mouse models and experimental techniques.

Key Insights and Ideas

  • AIM2 is a Microglial Culprit: The study strongly implicates AIM2 specifically within microglia as a driver of synaptic damage and cognitive decline in AD. This moves beyond general AIM2 involvement to pinpoint its cellular source.
  • AIM2 Drives Excessive Synaptic Pruning: The findings suggest that AIM2 in microglia promotes an overactive phagocytic state, leading to the detrimental removal of healthy synapses.
  • Complement Pathway is Key: AIM2's detrimental effects appear to be mediated, at least in part, through the activation of the classical complement pathway (C1q and C3), which is known to tag synapses for removal by microglia.
  • Targeting Microglial AIM2 is Protective: Selectively removing AIM2 from microglia rescued synaptic structure, function, and cognitive performance in AD models, highlighting a promising therapeutic avenue.

Key Results

  • AIM2 Upregulation in AD: AIM2 expression was significantly increased in the hippocampus of Aβ1-42-induced AD mice, primarily within microglia.
  • AIM2 Overexpression Impairs Cognition and Synapses: Overexpressing AIM2 in healthy mice led to impaired spatial learning and memory, reduced dendritic complexity, and decreased synaptic protein levels (PSD-95, MAP-2).
  • Microglial AIM2 Knockout Rescues Deficits: In AIM2-cKO-AD mice, cognitive impairments (NOR, MWM) and synaptic dysfunction (reduced PSD-95/MAP-2, impaired LTP) were significantly ameliorated compared to AD mice.
  • Reduced Microglial Phagocytosis: Microglial-specific AIM2 deletion reduced the colocalization of microglia (IBA1) with synaptic markers (PSD-95) and decreased CD68 expression, indicating reduced phagocytic activity.
  • Complement Pathway Modulation: AIM2 overexpression increased C1q and C3 levels and their deposition on synapses, which was reversed by microglial AIM2 knockout. Blocking the C3aR receptor also improved synaptic function and memory in AIM2-overexpressing mice.

Limitations and Future Work

The authors acknowledge several limitations:

  • Mouse Model Specificity: The Aβ1-42 injection model, while useful, does not fully recapitulate the complex, multifactorial pathology of human AD, which includes neurofibrillary tangles, aging, and vascular issues.
  • Localized Aβ: The Aβ1-42 peptide is injected focally, whereas Aβ deposition in human AD is more heterogeneous.
  • Translational Gap: Further validation in human postmortem tissue is warranted to confirm these findings in human AD.
  • Longitudinal Studies: Longitudinal studies are needed to track AIM2 protein levels in biofluids of AD patients, which could serve as a diagnostic biomarker.

Future work should focus on translating these findings to human AD and further elucidating the precise molecular mechanisms by which AIM2 interacts with the complement system and microglial phagocytosis.

Summary updated

Abstract

Our results demonstrated that microglial AIM2 plays a critical role in regulating synaptic plasticity and memory deficits associated with AD, providing a new direction for developing novel preventative and therapeutic interventions for this disease.
BibTeX
@inproceedings{ye2023conditional,
  author = {Lei Ye and Mengsha Hu and Rui Mao and Tan Yi and Min Sun and Junqiu Jia and Siyi Xu and Yi Liu and Xiaolei Zhu and Yun Xu and Feng Bai and Shu Shu},
  title = {{Conditional knockout of <scp>AIM2</scp> in microglia ameliorates synaptic plasticity and spatial memory deficits in a mouse model of Alzheimer's disease}},
  booktitle = {CNS Neuroscience \& Therapeutics},
  year = {2023},
  doi = {10.1111/cns.14555},
}
Figure